Replies to post #148055 on Biotech Values

[genisi]

MRK's lead BACE inhibitor - MK-8931

I thought they will do a smaller phase II for safety and biomarkers data only.

So according to today's PR

initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.

How long will this phase II be? and why treat "mild-to-moderate" when we know chances are moderate is too late?